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AbstrAct
We investigated the functional consequences following deletion of a microRNA 
(miR) termed miR-595 which resides on chromosome 7q and is localised within one 
of the commonly deleted regions identified for Myelodysplasia (MDS) with monosomy 
7 (−7)/isolated loss of 7q (7q-). We identified several targets for miR-595, including 
a large ribosomal subunit protein RPL27A. RPL27A downregulation induced p53 
activation, apoptosis and inhibited proliferation. Moreover, p53-independent effects 
were additionally identified secondary to a reduction in the ribosome subunit 60s. We 
confirmed that RPL27A plays a pivotal role in the maintenance of nucleolar integrity 
and ribosomal synthesis/maturation. Of note, RPL27A overexpression, despite showing 
no significant effects on p53 mRNA levels, did in fact enhance cellular proliferation. In 
normal CD34+ cells, RPL27A knockdown preferentially blocked erythroid proliferation 
and differentiation.  Lastly, we show that miR-595 expression appears significantly 
downregulated in the majority of primary samples derived from MDS patients with 
(−7)/(7q-), in association with RPL27A upregulation. This significant downregulation 
of miR-595 is also apparent when higher risk MDS cases are compared to lower risk 
cases. The potential clinical importance of these findings requires further validation.
IntroductIon
MicroRNAs (miRNAs) are short non-coding RNAs 
which play pivotal roles in a diverse range of cellular 
processes [1]. As current miRNA target identification 
assays are often associated with a lack of sensitivity and 
specificity, this led to our development of a novel assay 
to identify potential miRNA targets [2]. This assay relies 
upon functional activity rather than depending solely on 
computational algorithms addressing homology or binding 
to a putative target [3–5]. Furthermore, this methodology 
can aid identification of targets that are downregulated by 
mRNA cleavage or translation inhibition. 
We focused on miRNAs localised to chromosome 7, in 
particular miR-595 at 7q36.3. This miRNA is localised within 
one of the commonly deleted regions (CDR) identified 
for MDS with monosomy 7 (−7)/isolated loss of 7q (7q-)
[6–9]. We show, for the first time, that RPL27A, encoding a 
ribosomal subunit protein, is a target for miR-595.
It is well established that impaired ribosome 
biogenesis can induce nuclear stress. This phenomenon 
can be associated with the development of clinical entities 
collectively known as “ribosomopathies” which include 
several congenital disorders and bone marrow failure 
syndromes, such as Diamond Blackfan Anaemia (DBA), 
Shwachman-Diamond syndrome (SDS), Dyskeratosis 
Congentia (DC) and Cartilage-Hair Hypoplasia (CHH) 
syndrome, in addition to the acquired MDS subtype 
‘5q- syndrome’ [10, 11]. More recently, it has also 
been recognised that ribosomal stress can induce p53 
accumulation, although the mechanisms underlying this 
phenomenon remain complex (Figure 1). Marechal et al. 
were the first to demonstrate the complex interaction 
between RPL5, p53 and MDM2 [12]. Further studies 
have demonstrated that reduced expression of a range 
of ribosomal proteins, including RPS6, RPL22, RPL24, 
RPS19, RPS14 and RPL23, can all increase p53 levels 
whereas reductions in RPL11 and RPL5 actually decrease 
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p53 levels [13–20]. In contrast, the overexpression of 
RPL5, RPL26 and RPL11 and other ribosomal proteins, 
induced p53 expression [19–23]. Uniquely, both 
reductions and overexpression of RPL23 and RPS14 
augment p53 expression, highlighting the complex 
interaction of these ribosomal proteins and the p53 axis 
[18–24]. In this study, we focused on validating RPL27A 
as a novel target of miR-595. We investigated the effects 
of RPL27A knockdown on p53 activation, ribosome 
synthesis and maturation. Lastly, we investigated the 
expression of miR-595 in a cohort of patients with MDS.
results
Identification and validation of RPL27A as a 
target of miR-595 
Our novel assay is based on the directional cloning 
of a 3′UTR cDNA target ID library (Sigma, MREH01) 
derived from 10 different human tissues and 10 human 
cell lines, representing 16,923 unique genes, cloned 
downstream of a TKzeo fusion gene in plasmid p3’TKzeo 
conferring zeocin resistance and Ganciclovir sensitivity. 
The breast carcinoma MCF7 cell line, lacking miR-595, 
was hence transfected with this cDNA library and 
underwent zeocin selection. Expanded zeocin resistant 
cells underwent infection with either a pBabePuro vector 
expressing miR-595 or empty vector. After 48 hours, 
cells underwent puromycin selection and subsequent 
ganciclovir (GCV) counter-selection. Surviving colonies 
were expanded, genomic DNA isolated and PCR amplified 
using vector specific primers. Supplementary Figure S1 
displays one such amplification. Candidate amplicon 
bands were present in multiple independent samples 
and hence represented putative miR-595 targets. These 
bands of interest underwent purification and sequencing. 
A BLAST sequence search displayed a high degree of 
homology for two different transcripts; ribosomal protein 
L27A (RPL27A; 500 bp) and heat shock protein 14 
(HSPA14; 800 bp). We focused on validation of RPL27A 
as a target for miR-595 and establishing the biological 
function of RPL27A. 
Validation experiments were performed in the 
HeLa, HepG2, KG-1 and K562 cell lines. Each underwent 
transfection with either pBabepuro-miR-595 or empty 
vector followed by puromycin selection. Cells were 
screened for miR-595 expression by quantitative – Reverse 
Transcriptase PCR (qPCR) and demonstrated significantly 
increased miR-595 expression compared to wild-type 
(Figure 2A). Following miR-595 overexpression, RPL27A 
Figure 1: Ribosomal protein-MDM2-p53 interactions. Under steady state conditions, ribosome biogenesis occurs within the 
nucleolus and ribosome subunits are subsequently exported to the cytoplasm to facilitate formation of mature ribosomes and initiation of 
mRNA translation. MDM2 can mediate attachment of ubiquitin (Ub) molecules to p53, inducing p53 degradation and permitting normal 
cell proliferation. In contrast, ribosomal stress can impair ribosome biogenesis and disrupt ribosome assembly. This causes a release of 
free ribosomal proteins (RP), which interact with MDM2 and block its interaction with p53, resulting in p53 accumulation. Subsequently, 
activated p53 may cause cell cycle arrest, apoptosis, deregulated DNA repair or senescence.
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mRNA levels were decreased by 83% in KG-1 cells, 73% 
in K562 cells, 88% in HeLa cells and 55% in HepG2 cells 
respectively compared to controls (Figure 2B). RPL27A 
protein levels in both HeLa and HepG2 cells were also 
downregulated (Figure 2C). Lastly, HeLa wild-type 
cells and miR-595-transfected HeLa cells underwent 
additional transfection with a hairpin inhibitor directed 
against miR-595 (Miridian) and a control hairpin inhibitor 
(Dharmacon) and analysed for RPL27A mRNA and 
protein expression (Figure 2D). Wild-type HeLa cells 
showed no significant alteration in RPL27A expression 
levels following inhibitor transfection, whereas HeLa 
cells transfected with miR-595 showed reduced expression 
of RPL27A. This reduced RPL27A expression could be 
reversed with the miR-595 hairpin inhibitor (Miridian), 
resulting in a 4-5-fold upregulation of RPL27A mRNA 
transcripts and protein expression. 
Decreased expression of RPL27A causes p53 
activation 
We examined the effects of reduced RPL27A 
expression in HCT-116, HCT-116-p53–/–, K562 and 
HEL cell lines and compared these to the already 
well-established effects induced by RPS14 and RPL5 
downregulation. Two different lentivirus short-hairpin 
(sh) RNAs were chosen, RPL27A-sh2 and RPL27A-sh4, 
which decreased expression by 80% and 40% respectively 
at mRNA and protein levels. Efficient knockdown of both 
RPS14 and RPL5 via lentiviral shRNA was also achieved 
(Supplementary Figure S2A–S2D). 
In the p53-expressing HCT-116 cell line, RPL27A-
sh2 and -sh4 mediated knockdown resulted in a significant 
increase in p53 mRNA levels compared to control 
(p = 0.005 and p = 0.021 respectively). For the p53 
expressing HEL cells, an increase in p53 expression was 
only observed following RPL27A-sh2 (p = 0.027), RPS14 
knockdown resulted in significant p53 upregulation 
(p = 0.0149) whereas RPL5 depletion did not induce any 
significant changes (Figure 3A). 
MDM2 is a pivotal feedback regulator of the p53 
pathway. Depletion of RPL27A, RPS14 and RPL5 resulted 
in reduced MDM2 expression at both the transcriptional 
and post-transcriptional level in all cell lines except 
in K562 cells, where RPL27A-sh2 induced significant 
reductions at mRNA level only (Figure 3A and 3C). 
Co-immunoprecipitation assays demonstrated that 
endogenous RPL27A interacts with endogenous MDM2 
and RPL5 in HCT-116 cells (Supplementary Figure S3). 
To investigate if induction of p53 expression resulted 
in transcriptional activation, expression of the p53 targets 
p21 and Bax was determined. In HCT-116 cells, both 
p21 and Bax mRNA levels were significantly increased 
following both RPL27A-shRNA and RPS14-shRNA-
mediated downregulation. In contrast, RPL5 knockdown 
did not induce significant changes. In HEL cells, RPL27A-
sh2, RPS14 shRNA and RPL5 shRNA induced significant 
increases in both bax and p21 expression. As expected, 
for the null p53 cell lines, no changes in p21 and Bax 
expression were identified, indicating that p21 and Bax 
induction occurred in a p53-dependent fashion (Figure 
3B and 3D). Both RPL27A-sh2 and RPS14 shRNA, 
compared to controls, increased p53 protein expression 
in HCT-116 and HEL cells. Interestingly, knockdown of 
RPS14 also resulted in a decreased expression of RPL27A 
(Figure 3E). Of note, RPL27A overexpression in HCT-116 
cells showed no significant effect on p53 mRNA levels 
or alteration in the cell cycle profile but did induce 
proliferation (Supplementary Figure S4A–S4D). 
Decreased expression of RPL27A induces 
apoptosis and inhibits proliferation in a p53 
independent manner
Initially, proliferation assays were performed in both 
p53-expressing and p53-null cells to determine effects of 
RPL27A depletion (Figure 4A–4B). In both K562 and 
HEL cells, a significant reduction in cell numbers was 
detected by day 4, and increased over time, following 
RPL27A knockdown by RPL27A-sh2. This was also 
the case for RPS14 and RPL5 knockdown. RPL27A-sh4 
infection, however, displayed less effect on cell numbers. 
Unexpectedly, we did not observe significant differences 
in cell death between p53 expressing HEL cells and p53 
null K562 cells. To establish if this was truly a p53-
independent effect, we repeated knockdown experiments 
with RPL27A-sh2 in the p53 null cell line U937. Again 
we noted a decrease in cell numbers compared to control, 
although this was not lethal (Figure 4C).
Apoptosis assays using Annexin-V/7-AAD staining 
at Day 6 following shRNA infection were performed 
(Figure 4D–4H). HCT-116 infection with RPL27A-sh2 
induced significant increases in cells at the early stage 
of apoptosis (55%), as was the case with RPS14 (40%) 
and RPL5 (35%) knockdown. Of note, RPL27A-sh4, 
which induces < 50% RPL27A knockdown, only led to a 
25% increase in apoptotic cells. The HCT-116-p53-/- cell 
line also displayed significant increases in early (range 
15–20%) and late stages of apoptosis (8–10%). For HEL 
cells, a significant increase in the late stage of apoptosis 
was observed for all shRNAs (40–50%). However, in p53 
null K562 cells, depletion of RPL27A and RPS14 led to 
an increase in apoptotic cells by an average of 15–20% at 
both early and late stages. Lastly, U937 cells demonstrated 
a significant, but less marked, induction in apoptosis 
following RPL27A-sh2 infection.
RPL27A deficiency induces a reduction in 
ribosomal 60S and causes nucleolar disruption
Polysome profiling was performed to establish if 
RPL27A deficiency induced ribosomal defects. Profiling 
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Figure 2: Validation of RPL27A as a target for miR-595 by qRT-PCR and western blot analysis. Endogenous RPL27A 
mRNA and protein levels were determined in untransfected, pBabePuro empty vector (pBabe), and pBabePuro-miR-595 (miR-595) 
transfected cells. miR-595 expression levels were determined in untransfected and miR-595 transfected KG-1. K562, HeLa and HepG2 cells 
48 hrs after the miRNA transfection (A). To investigate if miR-595 overexpression downregulates RPL27A expression, RPL27A mRNA 
was quantified by qRT-PCR in untransfected cells, cells transfected with empty vector and cells transfected with miR-595. Downregulated 
expression of RPL27A occurred in all cell lines overexpressing miR-595, in contrast to cells transfected with pBabe empty vector and 
untransfected cells. Results represent three independent experiments; bars display the mean ± standard error of the mean (SEM) (b). HeLa 
and HepG2 cells were transfected with empty vector or miR-595. RPL27A protein expression is downregulated in HeLa and HepG2 cells 
expressing miR-595 compared to control. Tubulin was used as a loading control (c). HeLa cells which did not express miR-595 were 
transfected with either hairpin control inhibitor (HeLa+C) or miR-595 inhibitor (HeLa+ miR-595Inh). HeLa cells expressing miR-595 were 
also transfected with hairpin control or miR-595 inhibitor. Upregulated RPL27A mRNA and protein expression was evident in miR-595 
expressing HeLa cells which underwent transfection with the miR-595 inhibitor compared to controls (d, e).
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Figure 3: Decreased expression of RPL27A activates the p53 pathway. HCT-116 and HEL cell lines dually express MDM2 
and p53 mRNA. RPL27A and RPS14 depletion significantly augmented expression of p53 mRNA in HCT-116 cells compared to controls. 
RPL27A-sh2RNA, RPS14-shRNA and RPL5-shRNA reduced MDM2 expression in both cell lines (A). Increased expression of the p53 target 
genes p21 and Bax was induced by RPL27A and RPS14 depletion in HCT-116 and HEL cells (b). In the HCT116 p53−/− and K562 cell 
lines, MDM2 expression was reduced following RPL27A-shRNA2, RPS14-shRNA and RPL5-shRNA infection but no significant effects 
were noted for p21 or Bax expression. Bars display the mean results from three independent experiments ± SEM (p values were determined 
using two tail student t-test *p = < 0.05; **p = < 0.005)) (c, d). Protein expression of p53, MDM2 and RPL27A was determined following 
RPL27A-sh2 or RPS14-shRNA mediated knockdown. Tubulin was used as a loading control. In the HCT-116 and cell lines, depletion of 
RPL27A and RPS14 induced p53 expression and reduced MDM2 (e, G). In the HCT-116 p53−/− cell line, depletion of RPL27A and RPS14 
reduced MDM2 expression (F). No significant reduction in MDM2 protein expression was identified compared to empty vector following 
infection with either RPL27A shRNA and RPS14 shRNA in K562 cells (H). In all cell lines, infection with RPS14 shRNA, caused a 
reduction in RPL27A expression. Results are representative of 3 independent experiments.
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Figure 4: Reduction in RPL27A decreases cell proliferation and induces apoptosis. Proliferation was assessed by cell 
enumeration at 48-hour intervals. Significant reductions in K562 and HEL cells were determined by day 4 post-infection with RPL27A-sh2, 
RPL27A-sh4, RPS14 shRNA and RPL5-shRNA compared to controls (A, b). Although attenuated proliferation was also noted in the U937 
cells following RPL27A-sh2, this was less marked than in the other cell lines examined (c). Error bars represent the mean ± SEM from 
three independent experiments. Apoptosis was assessed via flow cytometric assessment of Annexin V and 7-ADD expression in HCT-116, 
HCT-116 p53−/−, K562 and HEL cells at day 6 following infection with empty vector, both RPL27A shRNAs, RPS14 shRNA and RPL5 
shRNA. Compared to controls, RPL27A depletion induced significant apoptosis in all 4 cell lines (d–G). Similarly, knockdown of RPS14 
and RPL5 induced significant apoptosis. In the U937 cell line, compared to empty vector, RPL27A-sh2 infection significantly increased the 
percentage of cells undergoing apoptosis but to a lesser degree than observed in the other cell lines (H). Columns display the mean results 
from three independent experiments ± SEM (*p = < 0.05; **p = < 0.005)).
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was performed in HCT-116, HCT-116-p53-/- and K562 
cells infected with empty vector, RPL27A-sh2 or RPS14 
shRNA respectively. Downregulation of RPL27A resulted 
in a reduction of the 60S subunit and slight increase in 
the 40S subunit in all three-cell lines  (Figure 5). Of note, 
RPL27A-sh4 was examined in HCT-116 cells where it 
induced a slight reduction in the 60S subunit only. 
Next, nucleolar staining was performed. HCT-116 
and HCT-116 p53-/- cells were infected with empty vector, 
RPL27A-sh2, RPS14-shRNA or RPL5-shRNA, underwent 
puromycin selection and subsequently were collected, 
fixed and stained with anti-fibrillarin antibody. Depletion 
of RPL27A, RPS14 and RPL5 resulted in abnormal 
dispersion of fibrillarin in the nucleolus (Figure 5). These 
characteristics may in part explain the p53-independent 
effects observed following RPL27A depletion.
RPL27A depletion induces early p53 dependent 
effects 
To investigate time-dependent effects following 
RPL27A depletion, we collected samples for analysis 
from HCT-116 and HCT-116 p53-/- cells at 48 hours post-
infection with RPL27A-sh2, RPS14 shRNA, RPL5 shRNA 
or control. RPL27A-sh2, RPS14 shRNA and RPL5 shRNA 
infection induced p53-dependent apoptosis. In contrast, 
no significant increase in apoptosis was observed in the 
p53 null cell line at this early time point (Figure 6A). 
Furthermore, MTT assays demonstrated reduced HCT-116 
cell viability following both RPL27A and RPS14 
depletion. In contrast, RPL5 depletion did not affect 
cell viability in either cell line (Figure 6B). Polysome 
profiling was performed on HCT-116 cells following 
RPL27A-sh2 infection (Figure 6C). Although RPL27A 
depletion reduced the 60S subunit, this was less marked 
than the later reduction observed on Day 6, suggesting that 
attenuation of the 60s subunit increases with time. 
RPL27A knockdown in normal CD34+ cells 
reduces cell proliferation and induces p53
For Peripheral Blood Mononuclear Cell (PBMC) 
derived CD34+ cells, both RPL27A and RPS14 shRNA 
reduced the expression of RPL27A and RPS14 mRNA 
respectively by ≈70% compared to control (Figure 7A) 
and RPL27A knockdown was confirmed by western 
blot analysis (Figure 7C). Despite an apparent decrease 
in p53 mRNA expression in both RPL27A and RPS14 
depleted cells, there was an increase in both p53 protein 
expression and p21 and Bax transcripts (Figure 7B 
and 7C). In addition, both RPL27A and RPS14 shRNA 
attenuated cellular proliferation as demonstrated by 
hypophosphorylation of Retinoblastoma protein (Rb) and 
a reduction in cell enumeration (Figure 7C, 7D).
Next, we established the effect of RPL27A 
knockdown on erythroid cells. Erythroid differentiation 
was assessed on day 10 by flow cytometric expression of 
the erythroid- specific CD71 and Glycophorin A (GlyA) 
positive cells within the gated live cell population. 
Marked reductions in both immature and mature erythroid 
cells were evident in RPL27A and RPS14 deficient cells 
respectively (Figure 7E). Apoptosis was assessed by 
Annexin V staining and confirmed increased apoptosis 
in erythroid cells (Figure 7F). Lastly, RPL27A deficiency 
significantly blocked erythroid and granulocyte/ 
macrophages (GM) colony formation as assessed by 
clonogenic assays. The reduction in erythroid forming 
colonies was the most prominent finding (Figure 7G–7J).
miR-595, RPL27A and RPS14 expression in MDS 
patients
The relative expression of miR-595, RPL27A and 
RPS14 in bone marrow CD34+ cells derived from 29 
MDS patients was compared to 4 controls. Supplementary 
Table S4 displays patient clinical details. As regards 
cytogenetics, 11 patients had −7/7q-, 6 patients had a 
complex karyotype inclusive of chromosome 7 anomalies, 
7 patients had del5q and 5 patients had a normal 
karyotype. P53 mutational status was not available for all 
patients. The microRNA miR-595 was detected in 27/29 
patients and 3/4 controls. Of note, miR-595 expression was 
significantly downregulated in MDS with −7/7q- MDS 
(n = 11) compared with normal karyotype MDS (n = 5). 
Furthermore, miR-595 was significantly downregulated in 
MDS with complex karyotype inclusive of chromosome 7 
anomalies (n = 6) compared with normal karyotype MDS 
(n = 5) (Figure 8A). Of note, in this cohort, RPL27A was 
significantly upregulated in patients with −7/7q- compared 
with 5q- patients. No significant expression changes were 
identified between the −7/7q- cohort and other cytogenetic 
groups. Lastly, we compared miR-595 expression between 
IPPS High Risk (HR) and low risk (LR) groups. miR-595 
expression appeared lower in HR disease when compared 
to LR disease, accompanied by higher expression of both 
RPL27A and RPS14 (Figure 8B–8F). These findings need 
confirmed in a larger cohort.
dIscussIon
Our novel assay identified several putative targets 
of miR-595, a microRNA residing on chromosome 7, 
including RPL27A and HSPA14. We hereby confirm, for 
the first time, that the ribosomal subunit RPL27A is a target 
for miR-595. Downregulation of RPL27A expression, to 
model haploinsufficiency, induced p53-mRNA and protein 
expression, accompanied by upregulation of p21 and Bax, 
in the HCT-116 cell line and upregulation of p21 and Bax 
in HEL cells. In contrast, in p53 null cells, expression 
levels of p21 and Bax did not significantly change, 
implying that RPL27A, akin to other ribosomal proteins 
functions through p53-dependent mechanisms. This finding 
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Figure 5: Depletion of RPL27A causes defects in 60S subunit maturation. Polysome profiling, utilising sucrose gradient 
fractionation, was performed in cells post infection with lentivirus-expressing RPL27A shRNAs, RPS14 shRNA and empty vector pLKO.1 
respectively. Polysomes were detected at A
245 
wavelength using a UV monitor at day 6 post infection and ribosomal native subunits 40S, 
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is consistent with a previous study investigating RPL27A 
in Sooty Foot Ataxia (SFA) mice [13–15, 17, 18, 25].
In our study, depletion of RPL27A, RPS14 and RPL5 
reduced MDM2 mRNA and protein expression in all cell 
lines except the K562 cell line. Moreover, we demonstrate 
that endogenous RPL27A interacted with both MDM2 
and RPL5 in HCT-116 cells. This suggests that RPL27A 
may well, at least in part, be working through MDM2 
to influence p53 expression. The BLAST alignment of 
RPL27A and RPL5 sequences resulted in two regional 
alignments with 85–89% identities, which supported 
the concept of possible binding between both moieties. 
Moreover, a computational based protein interaction 
application (BioGrid) predicted possible binding of 
RPL27A with both MDM2 and RPL5.
Sh-RNA mediated silencing of RPL27A, RPS14 
and RPL5 reduced proliferation capacity in both HEL and 
K562 cells, suggesting p53 independent effects. Decreased 
proliferation was additionally confirmed in the U937 
p53 null cell line. We also show that RPL27A depletion 
in both p53 functional and null cells is associated with 
increased apoptosis, suggesting both p53-dependent and 
independent effects.
It is well established that mutations or altered 
expression of ribosomal proteins may lead to dysregulated 
ribosome generation. We show that RPL27A knockdown 
via RPL27A-sh2 led to depletion of the 60s subunit 
accompanied by an increase in the 40s subunit. Our 
findings  contrast previous work in SFA mice where 
no effect on ribosome biogenesis was observed [17]. 
However, less efficient knockdown of RPL27A in that 
experimental setting may well explain this differing result. 
In addition, we highlight, for the first time, the importance 
of RPL27A in maintenance of nucleolar integrity and role 
in ribosome synthesis/maturation. Previous groups have 
suggested no effect on nucleolar integrity following either 
RPS14 or RPS19 knockdown [26, 27].
Knockdown of RPL27A in normal CD34+ cells 
resulted in increased p53 protein expression but not p53 
mRNA, akin to what was observed in previous studies 
investigating RPS14 and RPS19 knockdown [18]. 
One potential reason for this finding is a global inhibition 
of translation due to associated ribosome dysgenesis. 
Furthermore, reduction of RPL27A significantly 
attenuated cell proliferation and induced apoptosis. These 
observations were also seen with RPS14 knockdown and 
were in agreement with other studies, linking ribosomal 
haploinsufficiency to p53 activation. However, our initial 
work, and that of others have demonstrated additional 
p53 independent effects of RPL27A knockdown [26–28]. 
Functionally, we show that RPL27A depletion impaired 
proliferation of CD34+ cells. Marked reductions in both 
immature and mature erythroid cells was evident in 
RPL27A deficient cells similar to the effect of RPL27 
and RPS27 haploinsufficiency in DBA patients [29]. 
Of relevance, several other studies have described 
an upregulation of RPL27A during early erythroid 
development and hence suggest a pivotal role of RPL27A 
in erythropoiesis [30, 31]. For both −5q syndrome 
and DBA, mouse embryonic stem cell and zebra fish 
embryo models with depleted ribosomal proteins 
displayed anaemia regardless of p53 status, although 
we acknowledge the inherent limitations of these model 
systems [32–34]. 
Finally we demonstrated that miR-595 was 
significantly downregulated in MDS patients with 
-7/7q- compared with patients with normal karyotype. 
Interestingly, miR-595 was also significantly 
downregulated in MDS with complex karyotypes 
containing chromosome 7 anomalies and also when IPSS 
HR cases were compared to LR cases. Expression of 
RPL27A was higher in MDS with −7/7q- compared with 
5q- MDS and also in HR-MDS compared with LR-MDS. 
These findings are in agreement with previous work 
correlating ribosomal protein overexpression with both 
disease aggressiveness and progression [35, 36]. The 
prognostic significance of RPL27A requires further 
validation in a larger patient cohort.
In summary we have described that miR-595, 
located on chromosome 7q36.3, is a pivotal miRNA 
regulator of RPL27A. In vitro we have demonstrated both 
p53-dependent and independent effects following RPL27A 
deficiency, including attenuated cellular proliferation, 
apoptosis and defective ribosomal biogenesis. It is 
evident that RPL27A depletion leads to a severe cellular 
insult, which appears to have a predilection for early 
erythroid cell development. We show that miR-595 was 
significantly downregulated in MDS patients with −7/7q- 
compared with patients with normal karyotype. Given the 
chromosomal location of miR-595, at 7q36.3, the clinical 
relevance of these findings will require further exploration 
in the context of MDS patients who display chromosome 
7 anomalies.
60S and 80S are indicated. In HCT-116 and HCT-116 p53−/− cells, RPL27A depletion induced a significant reduction in the 60S subunit 
relative to control. As predicted, RPS14 shRNA reduced the 40S subunit compared to the relative control (A, B). RPL27A shRNA also 
reduced the 60S subunit in the K562 cell line (c). Results are representative of duplicate experiments. HCT-116 cell controls, post-infection 
with pLKO.1 empty vector or the ribosomal protein directed shRNAs as indicated, were fixed on slides and stained with an anti-fibrillarin 
antibody (green: nucleolar marker) on day 6. The nucleus was stained with DAPI (blue). Slides were analysed using a 40× objective 
Zeiss LSM780 confocal microscope and ZEN 2010 software. Results are representative of duplicate experiments. Disruption of nucleolar 
fibrillarin staining was evident in cells infected with shRNAs targeting the ribosomal proteins as indicated when compared to pLKO.1 
empty vector (d).
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Figure 6: RPL27A deficiency results in early p53-dependent apoptotic defects. HCT-116 and HCT-116 p53−/− cells were 
infected with control empty vector or shRNAs directed against RPL27A, RPS14 and RPL5 respectively and collected for analysis at 
48-hours post infection. For flow cytometric analysis, cells were stained with Annexin and 7-AAD. Cells in the upper left quadrant 
indicate Annexin positive, early apoptotic cells. Cells in the upper right quadrant indicate Annexin-positive/7-AAD-positive, late 
apoptotic cells. Compared to empty vector, RPL27A-sh2, RPS14 shRNA and RPL5 shRNA significantly induced apoptosis in the 
p53 containing HCT-116 cells only (A). Column diagrams represent mean % of apoptotic cells from three independent experiments ± 
SEM. (*p < 0.05; **p < 0.005). MTT assays were performed to delineate effects on cell viability (b). A significant reduction in cell 
viability was evident following RPL27A-sh2, -sh4 and RPS14 shRNA in HCT-116 cells only and not in the HCT-116 −/− cell line. 
Results are expressed as relative fold change mean ± SEM and are representative of three independent experiments (*p < 0.05; 
**p < 0.005). Polysome profiling (using sucrose gradient fractionation) was performed in HCT-116 cells infected with either RPL27A-sh2 
or empty vector only. Polysomes were detected at A
245
 using an ultraviolet monitor. RPL27A depletion reduced the 60S subunit compared 
with relevant controls; experiments performed in duplicate (c).
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Figure 7: RPL27A knockdown in normal CD34+ cells blocks haematopoietic stem cell proliferation and differentiation. 
Normal CD34+ cells underwent infection either with control, RPL27A-shRNA or RPS14-shRNA and samples collected for analysis on Day 
6. A significant reduction in RPL27A and RPL5 mRNA expression was evident following RPL27A-shRNA infection. Reduced RPS14 and 
RPL5 expression followed RPS14 shRNA infection (A). Upregulated expression of p53 mRNA and both p21 and Bax was induced following 
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either RPL27A or RPS14 shRNA infection (b). Depletion of RPL27A and RPS14 also resulted in increased p53 protein expression and 
hypophosphorylation of phospho-Retinoblastoma (pRB) protein (c). Enumeration of cells at 48-hour intervals post infection demonstrated 
reductions in cell numbers following infection with either RPL27A-sh2 or RPS14-shRNA compared to controls (d). Methycellulose colony 
formation assays were used to assess frequencies of progenitor cells following infection with either control, RPL27A-shRNA or RPS14 
shRNA. In both RPL27A and RPS14 deficient cells, the most prominent reduction was in the erythroid lineage. Data is representative 
of 4 independent experiments, bars represent the mean ± SEM. CFU: colony forming unit including all colony types except erythroid; 
CFU-E: colony forming unit erythroid only (e–H). Flow cytomety was performed on cells harvested on Day 10/11 post infection. Cells 
were labelled with a combination of conjugated flourometric antibodies including live/dead staining (780), an immature erythroid marker 
(CD71) and mature erythroid marker (Glycophorin A (GlyA)). Following either RPL27A-shRNA or RPS14 shRNA infection, a significant 
reduction in erythroid cells was evident compared with controls (I + J).
Figure 8: miR-595, RPL27A and RPS14 expression in MDS bone marrow CD34+ samples. First, miR-595 
expression was analysed in bone marrow CD34+ samples from 29 MDS patients (mir-595 was not detected in 2 patients). miR-595 
expression was significantly downregulated in MDS with −7/7q- MDS (n = 11) compared with normal karyotype MDS (n = 5). 
Significant differential expression of miR-595 was also evident between CD34+ cells derived from MDS patients with complex 
karyotype containing chromosome 7 anomalies compared to those from MDS patients with a normal karyotype (A). miR-595 was 
significantly upregulated in LR MDS compared with HR MDS (b). Relative expression was calculated using the ΔΔCT method 
and RNU6B was used to normalize all samples. Bars represent mean ± SEM. Next, RPL27A, RPS14 and RPL5 expression was 
determined in BM CD34+ samples from the same 29 patient cohort (c–F); Four control CD34+ samples were available. RPL27A 
was significantly upregulated in patients with −7/7q- compared with 5q- patients. Re-analysis according to IPSS score (HR = 17 
and LR = 12) demonstrated that RPL27A and RPS14 were significantly upregulated in HR MDS compared with LR MDS in this cohort. 
Bars represent mean ± SEM.
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MATeRIALS AnD MeThoDS
Methods not listed below are described in the 
online supplementary files
Cell culture and transfection
Adherent cells (MCF7, HeLa, HepG2, HCT-116 
and HCT-116 p53-/-) were cultured in Dulbecco modified 
essential medium (DMEM) media. Suspension cells 
(K562, KG-1, HEL and U937) were cultured in RPMI 
1640 media. Both culture media were supplemented with 
10% (v/v) Fetal Bovine Serum, 1% (v/v) L- Glutamine, 
penicillin-streptomycin, and 1% (v/v) sodium pyruvate. 
Cells were cultured under humidified condition at 37°C in 
a 5% CO incubator. The miRNA transfections and negative 
control pBabe transfections were performed using 
nucleofection technology according to the manufacturer’s 
instructions (Lonza). The miRNA sequence is listed in 
Supplementary Table S1.
novel functional assay for miR-595 identification
The micro-RNA miR-595 was cloned by PCR 
amplification of a ~1 Kb fragment obtained from human 
genomic DNA with primers incorporating the restriction 
sites BamHI and EcoRI. The resultant PCR fragment was 
cloned into pCR2.1-TOPO vector using pCRII-TOPO TA 
cloning kit (Invitrogen) and sequenced. Plasmid DNA 
was digested with BamHI and EcoRI and cloned into the 
retroviral vector, pBabepuro. The novel miRNA functional 
assay was performed as previously described (Gaken et al. 
2012) The 3′ untranslated region (3′UTR) cDNA library 
(MREH01, Sigma), derived from 10 different human 
tissues and 10 human cell lines and representing 16,923 
unique genes, was cloned downstream of the TKzeo fusion 
gene into Sfi1 sites in a p3′TKzeo vector. Isolated genomic 
DNA from the functional assay was amplified by PCR 
with p3′TKzeo specific primers flanking the cloning site 
(Forward GGGTCGACCTCGAATCCTTA and Reverse 
CGAGGCGGCCGACATGTTT). The PCR product was 
sequenced directly to identify targets for miR-595. Target 
identification and validation was applied as previously 
described (Gaken et al. 2012). 
Ribosome profiling
Cyclohexamide was added to those cell lines under 
investigation to obtain a final concentration of 100 μg/mL 
followed by incubation in a tissue culture incubator for 
15 minutes. Between 1–10 × 10  cells were subsequently 
harvested and washed with PBS containing 50 μg/mL 
cyclohexamide. Cell lysis, sucrose gradient centrifugation 
and polysome profiling were then performed as previously 
described (Fumagalli et al. 2009). Briefly, cells were lysed 
in polysome lysis buffer, incubated on ice for 15 minutes 
and centrifuged at 10,000 × g for 10 minutes at 4°C. 
Equal lysate, according to the Optical Density (OD) , was 
layered on top of a 10–50% (w/v) sucrose gradient and 
centrifuged for 1 hour and 57 minutes at 40,000 × g at 4°C 
in a SW41Ti rotor (Beckman). Gradients were fractionated 
using the polysome fractionator and Polysome profiles 
signals were detected using a UV monitor at A
254.
 
Patient samples
This cohort incorporated 29 bone marrow samples 
from patients with MDS, which underwent CD34+ 
selection. Normal CD34+ cell products were obtained 
from our Haemato-Oncology Tissue Bank (Human Tissue 
Authority; licence number 12223). Samples were used in 
accordance with ethics approval given by the UK National 
Research Ethics Service (NRES) (Approval Reference 08/
H0906/94).
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism version 6 (La Jolla, CA). Data was compared using 
paired t tests. P values < 0.05 were considered statistically 
significant.
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